Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (Nasdaq: XENE) announced equity inducement grants on December 4, 2025 to five new non-officer employees totaling 39,250 share options.
Xenon Pharmaceuticals (Nasdaq: XENE) announced equity inducement grants on December 4, 2025 to five new non-officer employees totaling 39,250 share options. The options carry an exercise price of $44.61, equal to Xenon’s closing share price on the grant date, vest over four years (25% after one year, then monthly vesting), and have a 10-year term. Grants were approved by the Compensation Committee and issued under Nasdaq Listing Rule 5635(c)(4) and the company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Terms are subject to each option agreement and continued service; the company highlighted its lead asset azetukalner in Phase 3 and earlier-stage ion channel programs.
In the Dec 5 session, XENE gained 0.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement details routine equity inducement grants totaling 39,250 options at an exercise pr...
Analysis
This announcement details routine equity inducement grants totaling 39,250 options at an exercise price of $44.61, vesting over four years with a 10-year term. The grants support ongoing hiring as Xenon advances its lead asset azetukalner in Phase 3 and pain programs in Phase 1. In context, the company recently reported Q3 cash of $555.3M and runway into 2027, while short interest of 8.94% and days to cover of 10.22 remain key risk metrics to monitor.
Key Figures
Inducement options granted:39,250 optionsExercise price:$44.61 per shareOption term:10 years+3 more
Inducement options granted
39,250 options
Aggregate equity inducement grants to five new non-officer employees
Exercise price
$44.61 per share
Equal to Xenon’s common share closing price on December 4, 2025
Option term
10 years
Term of the inducement share options under the 2025 plan
Vesting period
4 years
Inducement options vest over four years, service-based
Initial vesting tranche
25%
Vests on one-year anniversary of each employee’s start date
Subsequent vesting schedule
1/36 monthly
Remaining options vest monthly thereafter, subject to continued service
Historical Context
5 past events · Latest: Dec 03
5 events
Dec 03
Investor webinar
24h Move
+0.0%
Investor webinar on azetukalner epilepsy data and commercialization plans.
Nov 25
Clinical data update
24h Move
+0.0%
Announcement of new azetukalner OLE and epilepsy data at AES 2025.
Nov 06
Investor conferences
24h Move
+0.0%
Participation in Stifel and Jefferies healthcare investor conferences.
Nov 03
Earnings & update
24h Move
+0.0%
Q3 2025 results and pipeline update including Phase 3 and Phase 1 programs.
Oct 27
Earnings scheduling
24h Move
+0.0%
Scheduling announcement for Q3 2025 results and business update call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
"announced equity inducement grants to five new non-officer employees... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"The share options have an exercise price of $44.61 per common share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Phase 3 clinical trialsmedical
"azetukalner... in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD)"
Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.
Phase 1 developmentmedical
"NaV1.7 programs in Phase 1 development for the potential treatment of pain"
Phase 1 development is the first stage of testing a new drug or medical therapy in humans, focused on safety, how the body handles the treatment, and identifying a safe dose range. For investors it is an early milestone that reduces uncertainty—think of it like a prototype’s first test drive: passing it doesn’t prove long-term success but failing it can halt the program and materially affect a company’s value.
major depressive disordermedical
"Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD)"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
bipolar depressionmedical
"Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD)"
Bipolar depression is the low-mood phase of bipolar disorder, when a person experiences prolonged sadness, low energy, slowed thinking, and loss of interest in daily activities; think of it as the downward swing in a mood pendulum. It matters to investors because it shapes demand for treatments, the design and outcome of clinical trials, regulatory approval chances, and long-term healthcare costs—factors that affect the commercial potential of therapies and medical companies.
VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $44.61 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of December 4, 2025. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
